Celator Pharmaceuticals Inc., of Ewing, N.J., gained FDA fast track status for CPX-351 (cytarabine and daunorubicin) for the treatment of elderly patients with secondary acute myeloid leukemia. The ongoing phase III study of the therapy has completed enrollment, and the company said it expects induction response rate data to be available in the second quarter of this year, followed by overall survival data – the primary endpoint – in the first quarter of 2016.